Literature DB >> 31209635

Recent advances in invasive adenocarcinoma of the cervix.

Simona Stolnicu1, Lien Hoang2, Robert A Soslow3.   

Abstract

Endocervical adenocarcinomas (ECAs) are currently classified according to the 2014 World Health Organization (WHO) system, which is predominantly based on descriptive morphologic characteristics, considers factors bearing minimal etiological, clinical, or therapeutic relevance, and lacks sufficient reproducibility. The 2017 International Endocervical Adenocarcinoma Criteria and Classification (IECC) system was developed by a group of international collaborators to address these limitations. The IECC system separates ECAs into two major groups-those that are human papillomavirus-associated (HPVA) and those that are non-HPV-associated (NHPVA)-based on morphology (linked to etiology) alone, precluding the need for an expensive panel of immunohistochemical markers for most cases. The major types of HPVA ECA include the usual (with villoglandular and micropapillary architectural variants) and mucinous types (not otherwise specified [NOS], intestinal, signet-ring, and invasive stratified mucin-producing carcinoma). Invasive adenocarcinoma NOS is morphologically uninformative, yet considered part of this group when HPV positive. NHPVA ECAs include gastric, clear cell, endometrioid, and mesonephric types. The IECC system is supported by demographic and clinical features (HPVA ECAs develop in younger patients, are smaller, and are diagnosed at an earlier stage), p16/HPV status (almost all HPVA ECAs are p16 and/or HPV positive), prognostic parameters (NHPVA ECAs more often have lymphovascular invasion, lymph node metastases, and are Silva pattern C), and survival data (NHPVA ECAs are associated with worse survival). A move from the morphology-based WHO system to the IECC system will likely provide clinicians with an improved means to diagnose and classify ECAs, and ultimately, to better personalize treatment for these patients.

Entities:  

Keywords:  Classification; Endocervical adenocarcinoma; HPV; International Endocervical Adenocarcinoma Criteria and Classification

Mesh:

Year:  2019        PMID: 31209635      PMCID: PMC6864265          DOI: 10.1007/s00428-019-02601-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  60 in total

1.  Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma.

Authors:  E C Pirog; B Kleter; S Olgac; P Bobkiewicz; J Lindeman; W G Quint; R M Richart; C Isacson
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus.

Authors:  Kay J Park; Takako Kiyokawa; Robert A Soslow; Colleen A Lamb; Esther Oliva; Oliver Zivanovic; Margrit M Juretzka; Edyta C Pirog
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

3.  Cervical mesonephric hyperplasia lacks KRAS/NRAS mutations.

Authors:  Jelena Mirkovic; J Kenneth Schoolmeester; Frank Campbell; Alexander Miron; Marisa R Nucci; Brooke E Howitt
Journal:  Histopathology       Date:  2017-09-19       Impact factor: 5.087

4.  Cervical carcinomas with a micropapillary component: a clinicopathological study of eight cases.

Authors:  Colin J R Stewart; Mei H E Koay; Connull Leslie; Nathan Acott; Yee C Leung
Journal:  Histopathology       Date:  2017-12-14       Impact factor: 5.087

Review 5.  Pseudoneoplastic glandular lesions of the uterine cervix: a selective review.

Authors:  Marisa R Nucci
Journal:  Int J Gynecol Pathol       Date:  2014-07       Impact factor: 2.762

Review 6.  Clear cell tumors of the female genital tract.

Authors:  X Matias-Guiu; E Lerma; J Prat
Journal:  Semin Diagn Pathol       Date:  1997-11       Impact factor: 3.464

7.  The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study.

Authors:  H O Smith; M F Tiffany; C R Qualls; C R Key
Journal:  Gynecol Oncol       Date:  2000-08       Impact factor: 5.482

8.  Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.

Authors:  Alexi A Wright; Brooke E Howitt; Andrea P Myers; Suzanne E Dahlberg; Emanuele Palescandolo; Paul Van Hummelen; Laura E MacConaill; Melina Shoni; Nikhil Wagle; Robert T Jones; Charles M Quick; Anna Laury; Ingrid T Katz; William C Hahn; Ursula A Matulonis; Michelle S Hirsch
Journal:  Cancer       Date:  2013-08-23       Impact factor: 6.860

9.  Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era.

Authors:  M Bijoy Thomas; Jason D Wright; Aliza L Leiser; Dennis S Chi; David G Mutch; Karl C Podratz; Sean C Dowdy
Journal:  Gynecol Oncol       Date:  2008-04-03       Impact factor: 5.482

10.  Gastric-type adenocarcinoma of the cervix in a patient with Lynch syndrome: A case report.

Authors:  M Moat; R L O'Donnell; W G McCluggage; A Ralte; R J Edmondson
Journal:  Gynecol Oncol Rep       Date:  2014-03-13
View more
  16 in total

1.  Not Your Typical Adenocarcinoma: A Case of Mesonephric Adenocarcinoma of the Cervix With Fibroblast Growth Factor Receptor 2 (FGFR2) Mutation.

Authors:  Sindhu Devarashetty; Suma Sri Chennapragada; Richard Mansour
Journal:  Cureus       Date:  2022-05-18

Review 2.  [Revised German guidelines on the diagnosis and treatment of carcinoma of the uterine cervix-what's new for pathologists in 2021?]

Authors:  Lars-Christian Horn; Matthias W Beckmann; Markus Follmann; Martin C Koch; Monika Nothacker; Birgit Pöschel; Frederik Stübs; Dietmar Schmidt; Anne Kathrin Höhn
Journal:  Pathologie (Heidelb)       Date:  2022-02-21

3.  CDK6 increases glycolysis and suppresses autophagy by mTORC1-HK2 pathway activation in cervical cancer cells.

Authors:  Xiaoxi Zhang; Yunxia Sun; Siyao Cheng; Yanjing Yao; Xintao Hua; Yueyue Shi; Xiaoqin Jin; Jieli Pan; Miaofen G Hu; Pian Ying; Xiaoli Hou; Daozong Xia
Journal:  Cell Cycle       Date:  2022-02-15       Impact factor: 5.173

4.  Analysis of Clinicopathological Features of Cervical Mucinous Adenocarcinoma with a Solitary Ovarian Metastatic Mass as the First Manifestation.

Authors:  Shuanghuan Liu; Yunquan Guo; Bin Li; Huijuan Zhang; Rong Zhang; Shan Zheng
Journal:  Cancer Manag Res       Date:  2020-09-24       Impact factor: 3.989

5.  A case of non-HPV related primary endometrioid adenocarcinoma of the cervix.

Authors:  Kieran Seay; Bethany Bustamante; Seema Khutti; Marina Frimer
Journal:  Gynecol Oncol Rep       Date:  2020-05-01

Review 6.  Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists.

Authors:  Simona Stolnicu; Kay J Park; Takako Kiyokawa; Esther Oliva; W Glenn McCluggage; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2021-03-01       Impact factor: 3.326

7.  Incidence, clinical risk and prognostic factors for liver metastasis in patients with cervical cancer: a population-based retrospective study.

Authors:  Hang Liu; Xiangsen Ye; Di Li; Qian Yao; Yan Li
Journal:  BMC Cancer       Date:  2021-04-16       Impact factor: 4.430

8.  Locoregional recurrence via mucus-mediated extension following lung resection for mucinous tumors.

Authors:  Yo Kawaguchi; Jun Hanaoka; Yasuhiko Ohshio; Keigo Okamoto; Ryosuke Kaku; Kazuki Hayashi; Takuya Shiratori; Akira Akazawa; Mitsuaki Ishida
Journal:  BMC Cancer       Date:  2021-04-27       Impact factor: 4.430

9.  Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization.

Authors:  Hezhen Ren; Jennifer Pors; Christine Chow; Monica Ta; Simona Stolnicu; Robert Soslow; David Huntsman; Lynn Hoang
Journal:  J Pathol Transl Med       Date:  2020-08-31

10.  A retrospective study on incidence, diagnosis, and clinical outcome of gastric-type endocervical adenocarcinoma in a single institution.

Authors:  Anna Radomska; Daniel Lee; Heather Neufeld; Nancy Korte; Emina Torlakovic; Anita Agrawal; Rajni Chibbar
Journal:  Diagn Pathol       Date:  2021-07-31       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.